SCHEMBL4718672

SCHEMBL4718672

O=C(O)CC1Cc2ccccc2CCN1S(=O)(=O)NCCCCCNc1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 12/20 0.47
ITGAV P06756 12/20 0.47
ITGA2B P08514 7/20 0.47
ITGB5 P18084 4/20 0.47
ITGB1 P05556 2/20 0.47
HDAC1 Q13547 3/20 0.39
HDAC6 Q9UBN7 3/20 0.39
DRD2 P14416 2/20 0.39
ADRA1A P35348 2/20 0.39
DRD3 P35462 2/20 0.39
KDM4E B2RXH2 1/20 0.38
KDM6B O15054 1/20 0.38
KDM6A O15550 1/20 0.38
KDM4A O75164 1/20 0.38
KDM4B O94953 1/20 0.38
CHRNA1 P02708 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
KDM5A P29375 1/20 0.38
OPRM1 P35372 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4718121 0.83 ITGB3 (0.48) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4716851 0.81 DPP4 (0.51) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4718825 0.80 ITGB3 (0.48) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4718667 0.79 ITGB3 (0.51) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4718126 0.78 ITGB3 (0.46) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4762133 0.74 ITGB3 (0.52) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4761955 0.72 ITGB3 (0.52) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4718120 0.70 ITGB3 (0.54) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4716833 0.69 ITGB3 (0.56) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4718116 0.69 ITGB3 (0.53) ITGB3ITGAVITGA2BITGB5ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed